Northern Trust’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.66M Buy
78,598
+22,522
+40% +$1.28M ﹤0.01% 2392
2025
Q4
$2.37M Buy
56,076
+17,586
+46% +$984K ﹤0.01% 2897
2025
Q3
$2.19M Buy
38,490
+14,346
+59% +$475K ﹤0.01% 2991
2025
Q2
$624K Sell
24,144
-70,334
-74% -$790K ﹤0.01% 3585
2025
Q1
$964K Buy
94,478
+146
+0.2% +$1.91K ﹤0.01% 3303
2024
Q4
$1.32M Buy
94,332
+855
+0.9% +$15.1K ﹤0.01% 3254
2024
Q3
$1.82M Buy
93,477
+63,494
+212% +$1.21M ﹤0.01% 3059
2024
Q2
$558K Buy
29,983
+6,040
+25% +$127K ﹤0.01% 3468
2024
Q1
$336K Sell
23,943
-4,465
-16% -$46.7K ﹤0.01% 3706
2023
Q4
$241K Buy
28,408
+4,413
+18% +$33.4K ﹤0.01% 3830
2023
Q3
$214K Sell
23,995
-395
-2% -$3.8K ﹤0.01% 3787
2023
Q2
$210K Sell
24,390
-94,575
-79% -$1.01M ﹤0.01% 3811
2023
Q1
$1.25M Sell
118,965
-5,536
-4% -$167K ﹤0.01% 3140
2022
Q4
$4.22M Buy
124,501
+25
+0% +$1.21K ﹤0.01% 2588
2022
Q3
$5.98M Buy
124,476
+64,986
+109% +$3.87M ﹤0.01% 2355
2022
Q2
$3.39M Sell
59,490
-5,381
-8% -$340K ﹤0.01% 2757
2022
Q1
$5.25M Sell
64,871
-2,659
-4% -$394K ﹤0.01% 2561
2021
Q4
$13.7M Sell
67,530
-32,296
-32% -$7.01M ﹤0.01% 2029
2021
Q3
$26.9M Buy
99,826
+2,203
+2% +$530K ﹤0.01% 1575
2021
Q2
$25.1M Sell
97,623
-3,440
-3% -$952K ﹤0.01% 1730
2021
Q1
$30.3M Buy
101,063
+8,638
+9% +$2.69M 0.01% 1528
2020
Q4
$23.6M Sell
92,425
-2,415
-3% -$624K ﹤0.01% 1681
2020
Q3
$23.6M Sell
94,840
-3,538
-4% -$1.11M 0.01% 1498
2020
Q2
$34.2M Buy
98,378
+1,014
+1% +$316K 0.01% 1190
2020
Q1
$26.1M Buy
97,364
+2,886
+3% +$893K 0.01% 1211
2019
Q4
$30.6M Sell
94,478
-39,160
-29% -$11.4M 0.01% 1388
2019
Q3
$36.5M Buy
133,638
+1,906
+1% +$699K 0.01% 1210
2019
Q2
$70.3M Buy
131,732
+9,235
+8% +$4.63M 0.02% 754
2019
Q1
$61.7M Buy
122,497
+2,867
+2% +$1.7M 0.02% 815
2018
Q4
$59M Sell
119,630
-229
-0.2% -$138K 0.02% 745
2018
Q3
$110M Buy
119,859
+8,288
+7% +$7.07M 0.03% 521
2018
Q2
$81.7M Sell
111,571
-62,150
-36% -$71.7M 0.02% 656
2018
Q1
$277M Buy
173,721
+48,264
+38% +$62.2M 0.07% 271
2017
Q4
$112M Sell
125,457
-2,504
-2% -$1.48M 0.03% 522
2017
Q3
$46.1M Sell
127,961
-1,196
-0.9% -$374K 0.01% 1021
2017
Q2
$37.9M Buy
129,157
+8,686
+7% +$2.51M 0.01% 1154
2017
Q1
$42.4M Buy
120,471
+2,707
+2% +$608K 0.01% 1047
2016
Q4
$21.7M Buy
117,764
+13,125
+13% +$2.67M 0.01% 1555
2016
Q3
$27M Sell
104,639
-134
-0.1% -$34.5K 0.01% 1336
2016
Q2
$22.4M Sell
104,773
-1,084
-1% -$242K 0.01% 1437
2016
Q1
$21.8M Buy
105,857
+1,727
+2% +$332K 0.01% 1434
2015
Q4
$26.3M Buy
104,130
+2,458
+2% +$505K 0.01% 1285
2015
Q3
$16.7M Buy
101,672
+8,103
+9% +$1.43M 0.01% 1623
2015
Q2
$17.6M Sell
93,569
-1,703
-2% -$293K 0.01% 1687
2015
Q1
$15.7M Buy
95,272
+1,418
+2% +$291K ﹤0.01% 1763
2014
Q4
$21.8M Sell
93,854
-2,828
-3% -$604K 0.01% 1471
2014
Q3
$17.5M Sell
96,682
-4,568
-5% -$874K 0.01% 1613
2014
Q2
$19.5M Sell
101,250
-9,302
-8% -$1.65M 0.01% 1535
2014
Q1
$20.1M Sell
110,552
-689
-0.6% -$136K 0.01% 1566
2013
Q4
$18.9M Buy
111,241
+2,060
+2% +$332K 0.01% 1571
2013
Q3
$17.1M Sell
109,181
-949
-0.9% -$175K 0.01% 1585
2013
Q2
$19.1M Buy
+110,130
New +$16.9M 0.01% 1421

Other funds holding NKTR

Northern Trust's NKTR Position: Q1 2026 in Review

Northern Trust increased its Nektar Therapeutics (NKTR) stake by 40% in Q1 2026, buying an estimated $1.28M and bringing the position to 78,598 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Northern Trust first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $277M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Northern Trust held 78,598 shares of Nektar Therapeutics worth $5.66M as of Q1 2026.
  • Northern Trust bought 22,522 Nektar Therapeutics shares in Q1 2026, an estimated $1.28M.
  • Nektar Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2392 holding.
  • Northern Trust first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Nektar Therapeutics position peaked at $277M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.